Identification of a weight loss-associated causal eQTL in MTIF3 and the effects of MTIF3 deficiency on human adipocyte function

Mi Huang1, Daniel Coral1, Hamidreza Ardalani2, Peter Spegel2, Alham Saadat3, Melina Claussnitzer3, Hindrik Mulder4, Paul W Franks1,5*,†, Sebastian Kalamajski1*†

1Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden; 2Department of Chemistry, Centre for Analysis and Synthesis, Lund University, Lund, Sweden; 3Metabolism Program, Broad Institute of MIT and Harvard, Cambridge, United States; 4Unit of Molecular Metabolism, Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden; 5Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, United States

Abstract

Genetic variation at the MTIF3 (Mitochondrial Translational Initiation Factor 3) locus has been robustly associated with obesity in humans, but the functional basis behind this association is not known. Here, we applied luciferase reporter assay to map potential functional variants in the haplotype block tagged by rs1885988 and used CRISPR-Cas9 to edit the potential functional variants to confirm the regulatory effects on MTIF3 expression. We further conducted functional studies on MTIF3-deficient differentiated human white adipocyte cell line (hWAs-iCas9), generated through inducible expression of CRISPR-Cas9 combined with delivery of synthetic MTIF3-targeting guide RNA. We demonstrate that rs67785913-centered DNA fragment (in LD with rs1885988, r² > 0.8) enhances transcription in a luciferase reporter assay, and CRISPR-Cas9-edited rs67785913 CTCT cells show significantly higher MTIF3 expression than rs67785913 CT cells. Perturbed MTIF3 expression led to reduced mitochondrial respiration and endogenous fatty acid oxidation, as well as altered expression of mitochondrial DNA-encoded genes and proteins, and disturbed mitochondrial OXPHOS complex assembly. Furthermore, after glucose restriction, the MTIF3 knockout cells retained more triglycerides than control cells. This study demonstrates an adipocyte function-specific role of MTIF3, which originates in the maintenance of mitochondrial function, providing potential explanations for why MTIF3 genetic variation at rs67785913 is associated with body corpulence and response to weight loss interventions.

Editor’s evaluation

In this study, Huang et al. perform detailed functional genomics assays in cultured adipocytes to provide mechanistic insight underlying an important obesity GWAS locus. These studies not only demonstrate allele-specific effects of MTIF3 as a potential causal gene for variations in rs67785913 and rs1885988 alleles, but further provide a foundational framework from bridging GWAS associations to actionable pathways. The study strengths include genetic manipulation followed by detailed biochemical characterization to mimic and test the impacts of association, where future studies potentially involving in vivo characterizations could further inform the metabolic consequences of these observations.
Introduction
Over 650 million people are obese and often suffer from metabolic abnormalities, including dyslipidemia, type 2 diabetes, and hypertension (Adams et al., 2006; May et al., 2020). It is widely believed that obesity results from an interplay between genetic and environmental factors (Thomas, 2010), but the biological mechanisms behind these interactions are poorly understood.

Genetic variation (rs12016871) at MTIF3 (encoding the Mitochondrial Translation Initiation Factor 3 protein [Kuzmenko et al., 2014]) has been robustly associated with body mass index (BMI) in humans (Locke et al., 2015). Several subsequent studies have linked MTIF3 genetic variation with the response to weight loss interventions, including diet, exercise, and bariatric surgery (Papandonatos et al., 2015; Rasmussen-Torvik et al., 2015), and with weight-related effects of habitual diet (Nettleton et al., 2015). For example, analyses in two of the world’s largest randomized controlled weight loss trials (Diabetes Prevention Program [DPP] and Look AHEAD) found that homozygous minor allele carriers (rs1885988) were slightly more prone to weight gain in the control arm, yet achieved significantly greater weight loss at 12-month post-randomization and retained lost weight longer (18–36 months) than major allele carriers (Papandonatos et al., 2015). Elsewhere, the same locus has been associated with greater and more sustained weight loss following bariatric surgery (Rasmussen-Torvik et al., 2015).

Mtif3 loss in the mouse results in cardiomyopathy owing to impaired translation initiation from mitochondrial mRNAs and uncoordinated assembly of OXPHOS complexes in heart and skeletal muscle (Rudler et al., 2019). In the human hepatocyte-like HepG2 cell line, MTIF3 loss decreases the translation of the mitochondrial-encoded ATP synthase membrane subunit 6 (ATP6) mRNA without affecting cellular proliferation (Chicherin et al., 2020). No human genomic mutations leading to total MTIF3 deficiency have been reported, but the studies outlined above suggest that MTIF3 may influence obesity predisposition and weight loss potential by modulating mitochondrial function; thus, MTIF3 may play a key role in adipose tissue metabolic homeostasis, as adipocyte mitochondria not only provide ATP, but also impact adipocyte-specific biological processes such as adipogenesis, lipid metabolism, thermogenesis, and regulation of whole-body energy homeostasis (Gregoire et al., 1998; Boudina and Graham, 2014).

In this study, we aimed to experimentally dissect the molecular mechanisms that could underlie the correlation between MTIF3 genetic variation and weight loss intervention outcomes. We hypothesized that among the common genetic variants in MTIF3, one (or more) is causal for altered MTIF3 expression. Secondly, we hypothesized that MTIF3 content in human white adipocytes influences adipocyte-specific, obesity-related traits under basal and perturbed metabolic conditions. For the latter, we used glucose restriction to mimic the effects of in vivo lifestyle interventions focused on energy restriction and expenditure.

Results
rs67785913 is a regulatory variant for MTIF3 expression
The MTIF3 rs1885988 C allele is associated with enhanced weight loss and weight retention following lifestyle intervention trials in DPP and Look AHEAD cohorts (Papandonatos et al., 2015). In the GTEx database, the rs1885988 associates with an eQTL in subcutaneous fat (Figure 1A), with C allele carriers having significantly higher MTIF3 expression (normalized effect size: 0.15, p = 0.0000032).

To experimentally validate and fine map the potential causal DNA variation in the haplotype block tagged by rs1885988, we looked up all tightly linked (r² > 0.8) single-nucleotide polymorphisms (SNPs) in HaploReg database v4.1 (Ward and Kellis, 2012). We then PCR-amplified and cloned 12 DNA fragments from that haploblock, altogether comprising the linked SNP loci, into luciferase reporter plasmids. As shown in Figure 1D, by comparing the luciferase signals with minimal promoter (minP) construct, only one DNA fragment (F11), encompassing the rs67785913 locus, could enhance luciferase transcription. Coincidentally, the rs67785913 also shows an eQTL effect on MTIF3 expression in subcutaneous adipose tissue in GTEx database, with the major CT allele associated with lower expression than the minor CTCT allele (normalized effect size: −0.16, p = 3.0 × 10⁻⁸) (Figure 1B).

To demonstrate an allele-specific regulatory effect on MTIF3 expression, we then used CRISPR-Cas9 to substitute the major CT for the minor CTCT allele at the rs67785913 locus in the pre-adipocyte hWAs cell line. Due to rather low CRISPR editing efficiency of that locus, we needed to genotype over
Figure 1. Identification of rs67785913 as a causal cis-eQTL for MTIF3. (A) Violin plot of MTIF3 expression in subcutaneous adipose tissue for rs1885988 from Genotype-Tissue Expression (GTEx) Project eQTL. (B) Same as in (A), but for rs67785913. (C) Representative Sanger sequencing traces of rs67785913 CTCT/CTCT and CT/CT clones obtained after CRISPR/Cas9-mediated allele editing and single-cell cloning. (D) Normalized Z-score plot of luciferase reporter assays using vectors carrying different DNA fragments of the MTIF3 gene cloned into pGL4.23 luciferase reporter vector. Hypothesis testing was performed by comparing the transcriptional enhancer activity of each of the 12 vectors (F1–12) to the empty vector (minP). All data were plotted as mean ± standard deviation (SD), n = 4 independent experiments, p values are presented in each graph; ordinary one-way analysis of variance (ANOVA) was used for statistical analysis. (E) Relative MTIF3 expression (mRNA) in rs67785913 allele-edited cells 2 days before, at, or 2 days post-differentiation induction (day −2, 0, and 2, respectively). n = 3 clonal populations for CTCT/CTCT genotype, n = 5 clonal populations for CT/CT genotype, error bars show SD. (F) as in (E), but for GTF3A (mRNA) expression. Two-tailed Student’s t-test was used; p values are presented in each graph.

The online version of this article includes the following figure supplement(s) for figure 1:

Figure supplement 1. To test if rs67785913 affects adipogenic differentiation in hWAs cells, we differentiated the rs67785913 allele-edited cells (CTCT/CTCT vs. CT/CT) for 12 days.
700 single-cell clones to obtain five CT/CT and three CTCT/CTCT clones without random indels, as confirmed by Sanger sequencing (Figure 1C). We then examined MTIF3 expression in these clones at pre- and post-adipogenic differentiation induction, and found rs67785913 CTCT/CTCT to confer higher MTIF3 expression at all time points (Figure 1E), although without apparent change on adipogenic differentiation markers (Figure 1—figure supplement 1). As rs67785913 also correlates with an altered GTF3A expression in other tissues (e.g., muscle, lung), we also detected, but found no apparent difference in GTF3A expression in rs67785913-edited cells (Figure 1F).

**Generating inducible Cas9-expressing pre-adipocyte cell line (hWas-iCas9)**

Next, we intended to use the rs67785913-edited cells in functional genomics experiments to examine the phenotypic consequences of the eQTL. To conduct meaningful studies of gene × environment interactions...
interaction, it is desirable to use similarly differentiated cells with comparable baselines (e.g., similar triglyceride or mitochondrial content). Unfortunately, marginally different passage numbers between control and experimental groups can confound adipogenic differentiation. This problem can originate during single-cell cloning to create genetic knockouts/knockins, and became apparent with our rs67785913 allele-edited cells. While the mean values of adipogenic markers were similar in both rs67785913 genotypes (Figure 1—figure supplement 1), the variation between clones of the same genotype precluded the use of these cells in gene × environment studies. To circumvent this, we instead established an inducible Cas9-expressing pre-adipocyte cell line that allowed us to knockout MTIF3 after completed adipogenic differentiation. As illustrated in Figure 2, we co-transfected hWAs with two plasmids: one encoding piggyBac transposase, and the other carrying piggyBac transposon-flanked doxycycline-inducible Cas9 and constitutively expressed puromycin resistance genes. In this setup, piggyBac transposase drives the integration of the piggyBac-transposon-flanked genes, and transgenic cells are then selected and expanded in puromycin-supplemented culture medium. We have thus obtained an hWAs cell line with doxycycline-inducible Cas9 expression and maintained adipogenic differentiation capacity (henceforth called hWAs-iCas9). The Cas9-expressing differentiated cells could then be transfected with relatively low molecular weight synthetic single guide RNAs (sgRNAs) that complex with intracellularly expressed Cas9 and target the gene exon of interest to generate random indels (in essence, gene knockouts). We used this method here to determine the functional role of MTIF3 in adipocyte biology.

**Generation of MTIF3 knockout in hWAs-iCas9 mature adipocytes**

To investigate the role of MTIF3 in human adipocyte development and energy metabolism we generated stable MTIF3 knockouts in differentiated hWAs-iCas9 adipocytes. We designed Cas9-specific sgRNA to generate random indels in the exon expressed in all three MTIF3 protein-encoding transcripts (Figure 3A) and obtained a >80% reduction in MTIF3 protein levels in every experiment, as assessed by western blotting (Figure 3B–D, Figure 3—figure supplement 1, and Figure 4A, B). To assess off-target effects of CRISPR-Cas9, we also performed T7EI assays on PCR-amplified top 5 predicted off-target sites and did not observe any detectable off-targeting (data are not shown).

**MTIF3 knockout in mature adipocytes does not affect adipogenic marker or lipid content**

Although the MTIF3 knockout in hWAs-iCas9 cells was generated after the cells were differentiated, we wanted to ensure the genetic perturbation did not affect adipogenic markers or triglyceride content, as that could confound results from downstream functional studies. Incidentally, we observed that the quantities of the adipogenic markers, including ACC, FABP4, and FAS were comparable in control and MTIF3 knockout cells (Figure 3C, E; see also Figure 3—figure supplement 1). Similarly, there were no apparent differences in Oil-red O or total triglyceride content (Figure 3F, G).

**MTIF3 knockout disrupts mitochondrial DNA-encoding gene and protein expression, mitochondrial content, as well as mitochondrial OXPHOS assembly in hWAs-iCas9 adipocytes**

MTIF3 is a mitochondrial translation initiation factor; thus, we examined the effects of MTIF3 ablation on differentiated hWAs adipocyte mitochondrial respiration chain. Assessed by western blotting, the MTIF3 knockout cells had significantly decreased COX II (subunit of OXPHOS complex IV) and ND2 (subunit of OXPHOS complex I), trending decrease of CYTB (subunit of OXPHOS complex III), and unchanged ATP8 (subunit of OXPHOS complex V) content (Figure 4A, B). Moreover, using qPCR, we observed an altered expression of several mitochondrial DNA-encoding genes. Specifically, MTIF3 deficiency led to higher expression of MT-ND1, MT-ND2, a trending increase of MT-ND4, and lower expression of MT-ND3, and MT-CO3 (Figure 4C). In addition, we also found significantly reduced mitochondrial content in MTIF3 knockout adipocytes (Figure 4D). Taken together, the above data suggest MTIF3 knockout disrupts mitochondrial DNA-encoding gene and protein expression.

Next, we hypothesized the above observations could have originated from the insufficient MTIF3 supply during OXPHOS complex assembly (a role previously ascribed to MTIF3 [Rudler et al., 2019]). To test this, we used Blue Native-PAGE to examine OXPHOS complexes in mitochondria isolated from MTIF3 knockout adipocytes. MTIF3 deficiency led to decreased complex III, IV, and a trending
decreased complex V/III2 + IV1 assembly. In contrast, OXPHOS complex II assembly was significantly increased in MTIF3 knockout cells (Figure 4E, F). Interestingly, we also observed faster-migrating undefined bands in MTIF3 knockout adipocytes (Figure 4E), which could be single chain proteins, or mistranslation or degradation products. Lastly, The OXPHOS complex I + III2 + IV appeared to be less abundant in MTIF3 knockout mitochondria, although the bands appeared more diffuse and could not be quantified (Figure 4E).

Figure 3. MTIF3 perturbation in mature adipocytes does not affect adipocyte-specific protein expression or total triglyceride content. (A) An illustration of Cas9-specific single guide RNA (sgRNA)-binding site in the exon expressed in all three MTIF3 protein-encoding transcripts. (B) Representative Sanger sequencing of control and knockout hWAs mature adipocytes. (C) Immunoblots of adipocyte markers in scrambled control and MTIF3 knockout adipocytes, n = 5 independent experiments. (D) Quantitative analysis of MTIF3 band densities in (C). (E) Quantitative analysis of ACC, FABP4, and FAS band densities in (C). (F) Representative Oil-red O staining images of control and MTIF3 knockout in hWAs mature adipocytes. Scale bar is 200 µm. (G) Total triglyceride content in scrambled control (SC) and MTIF3 knockout (KO) cells. n = 3 independent experiments. Error bars show standard deviation in all plots. Statistical analysis was performed using two-tailed Student’s t-test, p values are presented in each graph. Uncropped blot images for (C) and raw.scn data files can be found in Figure 3—source data 1.

The online version of this article includes the following source data and figure supplement(s) for figure 3:

Source data 1. Raw data files for western blots shown in Figure 3C.

Figure supplement 1. To test the effects of MTIF3 knockout on adipogenic differentiation in hWAs-iCas9 cell line, we first induced MTIF3 knockout in hWAs-iCas9 pre-adipocytes, then differentiated them using standard adipogenic differentiation cocktail.

Figure supplement 1—source data 1. Raw data files for western blots shown in Figure 3—figure supplement 1A.
Figure 4. MTIF3 perturbation in mature adipocytes disrupts mitochondrial gene expression and OXPHOS complex assembly. (A) Immunoblots of mitochondrial genome-encoded proteins in scrambled control and MTIF3 knockout adipocytes. (B) Quantitative analysis of band densities in (A). (C) qPCR for mitochondrial gene expression in scrambled control and MTIF3 knockout adipocytes, n = 5 independent experiments. (D) Relative mitochondrial DNA content in scrambled control and MTIF3 knockout adipocytes, n = 5 independent experiments. (E) Immunoblots of mitochondrial Figure 4 continued on next page
**MTIF3 knockout affects mitochondrial respiration in hWAs-iCas9 adipocytes**

Having established the role of MTIF3 in adipocyte mitochondria OXPHOS complex assembly, and in mitochondrial gene expression, we then investigated the mitochondrial function in MTIF3-ablated differentiated hWAs adipocytes using Seahorse Mito Stress Test. Additionally, to avoid potential cofounders caused by the high glucose content in the differentiation medium, we adapted the cells to 1 g/l glucose growth medium for 3 days before running the assay. As shown in Figure 3, MTIF3 knockout cells exhibited lower basal oxygen consumption rate (OCR), as well as lower ATP-forming capacity, the latter estimated by calculating OCR decrease after blocking ATP synthase with oligomycin (Figure 5A–C). MTIF3 knockout cells also showed a trending decrease in maximal respiration OCR (Figure 5D). Furthermore, both MTIF3 knockout and control cells, had comparable proton leak OCR, non-mitochondrial respiration OCR and coupling efficiency (Figure 5E–G).

**MTIF3 knockout affects hWAs-iCas9 adipocyte endogenous fatty acid oxidation**

Next, we used Seahorse to assess the endogenous fatty acid oxidation in MTIF3 knockout versus control cells treated with etomoxir (an inhibitor of carnitine palmitoyl transferase). We found that MTIF3 ablation mimics the effect of etomoxir on basal endogenous fatty acid oxidation OCR. Furthermore, while etomoxir decreases basal fatty acid oxidation OCR in control cells, it does not markedly decrease it in MTIF3 knockout cells (Figure 6A, B).

**MTIF3 knockout affects hWAs-iCas9 adipocyte triglyceride content after glucose restriction challenge**

To mimic the interactions between MTIF3 content and dietary intervention on weight change, we generated hypertrophic control and MTIF3 knockout hWAs-iCas9 adipocytes and then used glucose-limited medium, not supplemented with free fatty acids (FFAs), to mimic energy restriction in vivo (schematic shown in Figure 6C). Triglyceride content decreased both in control and MTIF3 knockout cells after 3 days of different levels of glucose restriction when compared with 25 mM glucose medium. Interestingly, a more extensive decrease in triglyceride content occurred in control cells cultured in 1 mM glucose medium (p = 0.053), and a similar trending decrease, albeit with higher coefficient of variation, occurred in 3 and 5 mM glucose medium (Figure 6C).

**MTIF3 knockout does not affect lipolysis-mediated glycerol release in hWAs adipocytes**

Owing to the effects of MTIF3 ablation on triglyceride content and on fatty acid oxidation, described above, we then examined the effects of MTIF3 knockout on lipolysis. We measured basal, insulin-attenuated, and isoproterenol-stimulated glycerol release in differentiated hWAs cells. As shown in Figure 6D, in all three conditions, glycerol release in control and MTIF3 knockout cells was comparable. In addition, basal glycerol release in glucose-restricted conditions was similar (Figure 6—figure supplement 1), and significantly reduced in low glucose versus high glucose assay medium.
**Figure 5.** Cellular mitochondrial respiration in hWAs adipocytes. (A) The average oxygen consumption rate (OCR) traces during basal respiration, and after addition of oligomycin, FCCP, and rotenone/antimycin A. (B) Basal respiration OCR, n = 4 different cell passages. (C) ATP production OCR, n = 4 different cell passages. (D) Maximal respiration OCR, n = 4 different cell passages. (E) Proton leak OCR, n = 4 different cell passages. (F) Non-mitochondrial respiration OCR, n = 4 different cell passages. (G) Coupling efficiency, n = 4 different cell passages. Error bars show standard deviation. Statistical analyses were performed using paired Student's t-test in each condition, p values are presented in each graph.
Figure 6. MTIF3 perturbation affects adipocyte fatty acid oxidation. (A) A representative Seahorse oxygen consumption rate (OCR) trace for endogenous fatty acid oxidation assay. MTIF3 knockout and scrambled control adipocytes were treated with or without etomoxir for 15 min before the assay. Following the basal OCR measurement, oligomycin, FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone), and rotenone + antimycin A were added sequentially to measure the detection of ATP production OCR, maximal respiration OCR and non-mitochondrial respiration OCR. (B) Basal endogenous fatty acid oxidation OCR in scrambled control (SC) and MTIF3 knockout (KO) adipocytes, n = 4 independent experiments. (C) Upper panel: workflow of glucose restriction in differentiated adipocytes; Lower left panel: total triglyceride content in scrambled control (SC) and MTIF3 knockout (KO) adipocytes in 25 mM glucose conditions; Lower right panel: triglyceride content in adipocytes cultured in glucose-restricted conditions (5, 3, and 1 mM) relative to adipocytes cultured in 25 mM glucose, n = 4 independent experiments. (D) Z-score-normalized data for glycerol release in scrambled control and MTIF3 knockout adipocytes under basal, insulin-stimulated, and isoproterenol-stimulated conditions, n = 4 independent experiments.

Figure 6 continued on next page
MTIF3 knockout affects mitochondrial function- and fatty acid oxidation-related gene expression

Next, we examined how MTIF3 ablation affects the gene expression programmes pertinent to mitochondrial function, fatty acid oxidation, lipolysis and lipid catabolism. As shown in Figure 6E, MTIF3 knockout cells had decreased expression of the mitochondria-related MT-CO1, and the fatty acid oxidation-related ACADM and ACAT1, but unchanged expression of other genes involved in mitochondrial function and lipid metabolism (TFAM, TOMM20, PRDM16, CPT1B, ABHD5, PNPLA2, and ACACB).

MTIF3 knockout results in glucose level-depending alterations in metabolism

Considering the observed effect of MTIF3 ablation on mitochondrial function and fatty acid oxidation, we assessed the metabolite profile in MTIF3 knockout cells. Using combined GC/MS and LC/MS metabolite profiling resulted in relative quantification of 110 metabolites. First, we analyzed metabolite profiles at a global level using PCA. The score plot reveals a clear systematic difference in the metabolite profile between cells in 25 mM glucose versus in glucose restriction (Figure 7A). Interestingly, differences between MTIF3 knockout and control cells at 25 mM glucose are observed along principal component 1 (PC1), whereas differences between genotypes at glucose restriction are observed along PC2, suggesting the effect of MTIF3 ablation to depend on the calorie level. Next, to identify alterations in metabolite levels underlying this differential response, we analyzed data using orthogonal projections to latent structures discriminant analysis (OPLS-DA) separately at 25 mM glucose condition (two components \(R^2 = 0.82, Q^2 = 0.66\)) and at glucose restriction (two components, \(R^2 = 0.95, Q^2 = 0.52\)). These analyses revealed systematic differences between genotypes at both growth conditions (Figure 7B, C). Next, to examine whether the differences between genotype depended on growth condition, we combined the correlations from the two OPLS-DA models into a shared and unique structures plot (Figure 7D). These analyses revealed levels of intermediates in cytosolic metabolic pathways connected to the glycolysis, such as glycerate 3-phosphate, glycerol 2-phosphate, UDP-N-acetylglucosamine, and ribose 5-phosphate, to be lower in MTIF3 knockout cells at both glucose concentrations. Interestingly, levels of fatty acids, ranging from 9 to 17 carbons and including several odd-chain fatty acids, were lower in the MTIF3 knockout cells only at 25 mM glucose condition. At glucose-restricted conditions, levels of both essential and non-essential amino acids were lower in the knockout. Finally, we analyzed data using two-way analysis of variance (ANOVA), incorporating glucose concentration and genotype, thereby providing information on effects at the individual metabolite level. These analyses revealed 18 and 20 significantly different metabolites between control and MTIF3 knockout cells at 25 mM glucose condition and glucose-restricted conditions, respectively (\(q < 0.05\)). These included ribose 5-phosphate, glycerate 3-phosphate, glycerol 2-phosphate, and glycerol 3-phosphate (Figure 7E).

Discussion

Excessive weight gain caused by dietary excess, and its effects on adipocyte lipid metabolism, can cause life-threatening disease (Appleton et al., 2013; Denis and Obin, 2013; Chu et al., 2017; Lotta et al., 2018). Findings from clinical trials (Papandonatos et al., 2015), a bariatric surgery case series (Rasmussen-Torvik et al., 2015) and epidemiological cohorts (Nettleton et al., 2015) showed the MTIF3 variation modulates weight loss-promoting exposures on body weight (see also UK Biobank analysis in Supplementary file 1b). Here, we validated MTIF3 rs1885988 C allele correlates with higher MTIF3 expression in subcutaneous fat tissue, and our in vitro luciferase reporter assay and
CRISPR-Cas9 genome editing results revealed that the tightly linked rs67785913 variant is likely to be the actual eQTL for \( \text{MTIF3} \) expression (Figure 1).

Pre-adipocyte cell lines have been used extensively for studying adipogenic differentiation (Ruiz-Ojeda et al., 2016), but their application for lipid metabolism studies has been limited, especially in the context of gene–environment interaction. This is largely due to the variation of differentiation capacity across cell passages (Poulos et al., 2010) and differential genetic effects on adipocyte differentiation (Kamble et al., 2020), which can alter baseline phenotypes in differentiated cells. Therefore, we established an inducible Cas9-expressing human pre-adipocyte cell line (hWAs-iCas9), which enabled us to generate gene knockout of interest in differentiated adipocytes, thus circumventing these limitations (Figure 2). Using the inducible knockout cell model, we then tested interactions between \( \text{MTIF3} \) and environmental changes (lifestyle mimetics). Our data reveal that \( \text{MTIF3} \) deficiency mediated disrupted mitochondrial respiration, probably as a consequence of decreased OXPHOS.

Figure 7. Mass spectrometry-based metabolomics data for control (SC) and \( \text{MTIF3} \) knockout (KO) cells in 25 mM glucose (NF, normal feeding) and 5 mM glucose (GR, glucose-restricted) conditions. (A) Principal component analysis (PCA) score plot displaying the discrimination between \( \text{MTIF3} \) knockout and control cells in normal and glucose-restricted conditions (PC1: 28%, PC2: 19%). (B) Orthogonal projections to latent structures discriminant analysis (OPLS-DA) score plot showing classification of \( \text{MTIF3} \) knockout and control cells in 25 mM glucose condition. (C) OPLS-DA score plots showing classification of \( \text{MTIF3} \) knockout and control cells in glucose-restricted condition. (D) Shared and unique structures (SUS) plot, based on OPLS-DA models in (B, C), showing glucose concentration-dependent differences between \( \text{MTIF3} \) knockout and control cells. (E) Box plots showing the abundance of some of the significantly altered metabolites in normal and \( \text{MTIF3} \) knockout cells in normal and glucose-restricted conditions. Statistical analysis was performed using two-way analysis of variance (ANOVA) test, \( p \) values are presented in each graph.
complex assembly. This led to perturbed cellular functions, including reduced fatty acid oxidation and a trending increase in intracellular triglyceride content. These data indicate that MTIF3 plays an important role in lipid metabolism in adipocytes.

In adipose tissue, mitochondria play an essential role not only by ensuring ATP supply but also by triggering cellular signaling pathways that require reactive oxygen species generated by OXPHOS complexes I and III (Tormos et al., 2011). These, and complexes IV and V, are partially encoded by mitochondrial DNA (Maechler and Wollheim, 2001). The post-transcriptional rate-limiting translation step can be promoted by MTIF3, as it facilitates initiation complex formation on mitochondrial 55S ribosomes in the presence of MTIF2, fMet-tRNA, and poly(A,U,G) (Bhargava and Spremulli, 2005). Previous studies have shown that loss of MTIF3 results in an imbalanced assembly of OXPHOS complexes in muscle and heart in mouse (Rudler et al., 2019) and decreased translation of ATP6 mRNA in hepatocyte-like HepG2 cells (Chicherin et al., 2020). Our data show that in adipocytes MTIF3 deficiency results in lower content of mitochondrial DNA-encoding proteins and altered expression of several mitochondrial DNA-encoding genes. Furthermore, it leads to disassembly of mitochondrial respiration OXPHOS complex, along with impaired mitochondrial respiration rate (Figures 4 and 5). Altogether, our results suggest that MTIF3 vastly affects the mitochondrial electron transport chain.

Mitochondrial dysfunction in white adipose tissue has been frequently associated with obesity (Kaaman et al., 2007), with the presumed mechanisms being decreased fatty acid oxidation and ATP production (reviewed in Heinonen et al., 2020). We have found that one causal link connecting these factors may be the MTIF3 content (Figures 5 and 6). Furthermore, a previous study described an inverse relationship between mitochondrial capacity and weight change (Jokinen et al., 2018); thus, conceivably, any genetic variation-modulated change in MTIF3 expression could influence a dietary intervention outcome. We attempted to test this hypothesis in vitro, exposing hypertrophic adipocytes to glucose restriction, thereby mimicking weight loss-promoting exposures in vivo. We found that MTIF3-deficient adipocytes exposed to glucose restriction challenge responded less through changed triglyceride content, indicating limited capacity for lipid metabolism under glucose restriction (Figure 6). Intriguingly, we did not observe altered lipolysis (glycerol release) in MTIF3 knockouts, either in the presence or absence of insulin and isoproterenol, or during glucose restriction. Here, we speculate that MTIF3 knockouts, having reduced fatty acid oxidation, re-esterify the released fatty acids to triglycerides, and thus retain more triglycerides during glucose restriction.

Mitochondrial function is robustly associated with insulin sensitivity (Böhm et al., 2020; Pietiläinen et al., 2008; Heinonen et al., 2015), both of which can be improved through lifestyle intervention aiming at weight loss (Phielix et al., 2010; Toledo et al., 2007; Larson-Meyer et al., 2006; Civitarese et al., 2007). Furthermore, impaired adipocyte differentiation derived from mitochondrial dysfunction in adipose tissue often associates with insulin resistance in humans and animal models (Sakers et al., 2022; Zhu et al., 2022). In our study, we did not observe impaired adipocyte differentiation due to MTIF3 deficiency or rs67785913 eQTL. These results, however, may not be directly translatable to in vivo conditions, in part because in vitro differentiation protocols employ relatively highly concentrated adipogenic compounds. Further in vivo studies are therefore needed to establish any link between MTIF3 content and insulin resistance. Similarly, long-term in vivo studies on the effect of altered MTIF3 expression on body weight are warranted to illuminate the translatability of the short-term or low effect size in vitro experiments (e.g., Figures 5 and 6). We envisage that the MTIF3 effect on adipocyte metabolism, while not dramatic in some of the presented data, could translate into larger effect size over time in vivo. Here, MTIF3 effect on metabolism in other tissues (e.g., muscle) would further contribute to body weight regulation. Lastly, one should bear in mind that our in vitro data were generated in cells highly depleted of MTIF3, and the extent to which a more moderate MTIF3 deficiency in vivo (e.g., conferred by common genetic variants) influences adipogenic differentiation or long-term diet-induced weight loss is currently unknown.

Finally, the metabolomic analysis added another dimension to the role of MTIF3 in regulating adipocyte metabolism (Figure 7). The lower content of glycolysis intermediates and odd-chain fatty acids in MTIF3 knockout adipocytes could indicate blunted lipogenesis, while the decreased essential and non-essential amino acid level in MTIF3 knockout cells under glucose restriction could be an adaption to the lower energy supply owing to impaired mitochondrial function (Hansson et al., 2004). The metabolite data, and the earlier described lower fatty acid oxidation capacity of MTIF3-deficient cells, suggest that MTIF3 plays a vital role in triglyceride metabolism in adipocytes, and provides
further insight into the previously reported role of this protein on weight loss induced by dietary intervention (Papandonatos et al., 2015).

In summary, we experimentally demonstrated that the common genetic variant rs67785913 is a functional polymorphism that causes modulated MTIF3 expression. Our functional genomics studies demonstrate that MTIF3 is essential for mitochondrial electron transport chain complex assembly, mitochondrial function, and lipid metabolism in human adipocyte cell lines. MTIF3 content may also influence adipocyte triglyceride content in conditions that mimic dietary restriction, reflecting a gene x environment interaction. Since our findings show that higher MTIF3 content in adipocytes increases mitochondrial function, this helps explain the previously observed interaction between MTIF3 locus and weight loss interventions. Furthermore, this suggests, although it remains to be demonstrated, that people who carry genetic variants that increase MTIF3 expression (e.g., the rs67785913 CTCT allele) may benefit more from lifestyle interventions targeting weight loss.

Lastly, we established a novel, efficient, and simple method to generate gene knockouts in differentiated adipocyte cell lines, and the method should be suitable for generating other gene knockouts.

Materials and methods

Allele-specific MTIF3 expression in subcutaneous adipose tissue

Data and plots presented in this manuscript for allele-specific MTIF3 expression in subcutaneous adipose tissue were obtained from GTEx Portal (https://www.gtexportal.org/home/) on 10/5/2022.

Cell culture

A human white pre-adipocyte cell line (hWAs) was previously isolated and immortalized from human subcutaneous white adipose tissue of a female subject, aged 56 with a BMI of 30.8. The generation and characterization of hWAs were described previously (Xue et al., 2015), and the cell line was kindly shared by Professor Yu-Hua Tseng (Joslin Diabetes Center, Harvard Medical School, USA). hWAS cells. For expansion, cells were cultured in 25 mM Dulbecco’s Modified Eagle Medium (DMEM) with GlutaMAX (10566016, Thermo Fisher Scientific), 10% fetal bovine serum (FBS; HyClone, GE Healthcare, Uppsala, Sweden), and 1% (100 U/ml) penicillin/streptomycin (15140122, Thermo Fisher Scientific). The cells were passaged at 90% confluence, and tested negative for mycoplasma.

DNA isolation and luciferase reporter assays

Genomic DNA was isolated from hWAs cells using DNeasy Blood and Tissue kit (69506, QIAGEN) according to the manufacturer’s manual. To fine map the transcriptional regulatory regions in the MTIF3 locus, we first identified the common genetic variants which were in tight linkage disequilibrium ($r^2 \geq 0.8$) with the lead variant rs1885988 in HaploReg v4.1 (Ward and Kellis, 2012). The thus identified 31 SNPs were tiled down into 12 DNA segments of the MTIF3 gene, as shown in Supplementary file 1a. These segments were then PCR amplified from hWAs DNA, all ranging from 700 to 1600 bp in size (depending on PCR primer design constraints), and with all SNP loci located several hundred bp from the ends of each fragment. The PCR primers were also designed to include flanking KpnI and EcoRV sites to allow cloning into the pGL4.23 minimal promoter luc2 luciferase reporter vector (Promega). For the reporter assays, hWAs were seeded into 96-well plates, and on the following day transfected with 95 ng of the pGL4.23 vectors and 5 ng pGL4.75 CMV-Renilla reporter vectors (for normalization), using Lipofectamine 3000 (Thermo Fisher Scientific), in technical duplicates. Two days after transfection, the luc2 and Renilla signals were detected using Dual-Glo Stop&Glo reagents (E2920, Promega). The averages of technical duplicates were used to calculate luc2:Renilla ratios, which were then Z-score normalized to allow statistical evaluation across four independent experiments.

gRNAs and ssDNA design for CRISPR/Cas9 mediated editing of rs67785913 in hWAs cells

To edit the rs67785913 CT allele to the minor CTCT allele in hWAs cell genome, CRISPR/Cas9 D10A nickase (Alt-R S.p. Cas9 D10A Nickase V3, IDT) and two sgRNAs, and an ssDNA donor template were used. The sgRNA spacer sequences were: 5'-TTCTAATAAGAAAATTCCCTAA-3' and 5'-GAAGAAAA AGGGGGGACACG-3'. The ssDNA sequence was 5'-TGTGGACCTCGAGCTGGCTGTTTGAGGAA TTTCATTGAGAGAAAAAGAGGGGGGACACGGGCCCCAGACCCCCAGACCCCGGTTCGA
All oligonucleotides, sgRNAs, and ssDNA were purchased from Integrated DNA Technologies. The transfection was performed using Nucleofector 2b device (program A-033) (Lonza, Sweden) in nucleofector reagent L (Lonza, Sweden) mixed with 5 × 10^5 hWAs cells, 120 pmol Cas9 nickase, 104 pmol sgRNA, and 300 pmol ssDNA. To increase the homology directed repair (HDR) editing efficiency, cells were incubated at 32°C for 2 days in growth medium containing 30 μM HDR enhancer (Alt-R HDR Enhancer V2, IDT). Subsequently, cells were transferred to 37°C for 3 days. For single-cell cloning, the hWAs cells were seeded at low density (2 cells/well in a 96-well plate) and allowed to expand for 3 weeks. Then the genomic DNA was extracted using QuickExtract DNA Extraction Solution (Lucigen) from the apparent single-cell clonal populations. To identify the allele-edited homozygous clones, PCR was used to amplify the DNA fragment surrounding rs67785913 using primer pairs as below: Forward 5′-GATT TGCA GGTG AGCA GACA, Reverse 5′-ACTT GGAA ATGG CCAA GATG; the amplicon was then subjected to Sanger sequencing to confirm the DNA sequence of each clone.

**Generation of inducible CRISPR/Cas9-expressing hWAs cell line (hWAs-iCas9)**

hWAs cells were first seeded at 80,000 cells/well in 6-well plates and transfected with 200 ng Super PiggyBac transposase (PB210PA-1, System Biosciences) and 500 ng pPB-rtTA-hCas9-puro-PB plasmid (kind gift from Dr. William Pu) (Wang et al., 2017) using Lipofectamine 3000 (Thermo Fisher Scientific). The plasmid carries a doxycycline-inducible promoter driving the expression of Cas9, and a puromycin resistance gene, all flanked by piggyBac transposon integration sequences. After 2 days, the transfected cells were selected and expanded for 3 weeks in growth medium with 1 μg/ml puromycin, to obtain cells with genomically integrated inducible Cas9 construct.

**Differentiation of hWAs-iCas9 pre-adipocytes into mature adipocytes**

hWAs-iCas9 pre-adipocytes were seeded into 24- or 96-well plates at the density of 40,000 or 8000 cells/well, respectively. After 3 days, the cells reached confluency and were then incubated for 12 days with the differentiation cocktail, with medium changes every 3 days, as described before (Shamsi and Tseng, 2017). To increase the accumulation of lipid droplets, 30 μM FFA (Linoleic Acid-Oleic Acid-Albumin) (L9655, Sigma-Aldrich) was added to the differentiation medium (Aprile et al., 2020).

**CRISPR/Cas9 guide RNA design and off-targeting check**

To generate MTIF3 knockout adipocytes, guide RNA spacer sequence targeting MTIF3 exon 5, expressed in all known MTIF3 protein-encoding transcripts (as reported at https://www.ensembl.org), was selected. The spacer sequence was 5′-GCAATAGGGGACACTGTGC-3′, and full-length sgRNA was purchased from IDT. Furthermore, the hWAs genomic sequence surrounding the gRNA-binding site was amplified by PCR using the primers 5′-CCACTTTGCTTGGGGACAGT-3′ and 5′-CTGGGAATG GTGTTGAAATC-3′, then analyzed by Sanger sequencing to ensure sequence match between gRNA spacer and the intended target locus. The potential off-target sites were predicted using CRISPR-Cas9 guide RNA design checker (https://eu.idtdna.com), and the genomic regions surrounding the top 5 off-target sites were PCR amplified from the genomic DNA extracted from MTIF3-knockout and scramble control cells. The amplicons were then analyzed for any heteroduplexes generated by off-targeting using T7EI assay (IDT, Alt-R Genome Editing Detection Kit).

**sgRNA transfection and MTIF3 knockout in mature adipocytes**

After 12 days of differentiation, Cas9 expression was induced in mature adipocytes by adding 2 μg/ml doxycycline to the growth medium. On the following day, 30 nM pre-designed sgRNA was delivered into the cells using Lipofectamine RNAiMAX (13778075, Thermo Fisher Scientific) according to the manufacturer’s protocol; in parallel, 30 nM negative control crRNA (1072544, IDT) was used to transfect the scrambled control cells. One day post-transfection, cells were washed with phosphate-buffered saline (PBS) and incubated in normal growth medium for at least 3 days before functional assays carried out.
**Oil-red O staining**
After MTIF3 knockout, the differentiated white adipocytes were washed twice with PBS and fixed for 10–20 min with 4% buffered formalin at room temperature. The cells were then stained with Oil-red O solution for 30 min at room temperature, followed by five washes with distilled water. The stained cells were visualized using light microscopy.

**Glucose restriction challenge for hWAs-iCas9 adipocytes**
The hWAs-iCas9 adipocytes were firstly differentiated to mature adipocytes as described above (in FFA-supplemented medium), then the MTIF3 knockouts and scrambled controls were generated, also as described above. After 3 days, the mature adipocytes were incubated in DMEM medium (11966025, Thermo Fisher Scientific) without FFA, and supplemented with different glucose concentrations (5, 3, and 1 mM) for the glucose restriction test. The cells were then incubated for 3 days, and the triglyceride content was determined as described above.

**RNA isolation and qPCR gene expression assays**
Total RNA was extracted from cells using RNeasy plus Kit (74034, QIAGEN) together with Qiazol reagent (79306, QIAGEN). RNA purity was assessed using Nanodrop (Nanodrop, Wilmington, USA), and cDNA was synthesized using SuperScript IV Vilo Master Mix (11756500, Thermo Fisher Scientific). Then, RT-qPCR was performed on ViiA7 qRT-PCR system (PE Applied Biosystems, Foster City, CA, USA), using predesigned Taqman assays following the manufacturer’s instructions. The Taqman assays (Thermo Fisher Scientific, Uppsala, Sweden) were: MTIF3 (Hs00794538_m1), GTF3A (Hs00157851_m1), ADIPOQ (Hs00977214_m1), PPARG (Hs00269972_s1), SREBF1 (Hs02561944_s1), FASN (Hs01005622_m1), TFAM (Hs0173348_g1), MT-CO1 (Hs02596864_g1), PRDM16 (Hs00223161_m1), TOMM20 (Hs03276810_g1), CPT1B (Hs00189258_m1), HGNC (Hs00936584_m1), ACAT1 (Hs00608002_m1), ABHD5 (Hs01104373_m1), PNP1A2 (Hs00386101_m1), ACACB (Hs01565914_m1), MT-ND1 (Hs02596873_s1), MT-ND2 (Hs02596874_g1), MT-ND3 (Hs02596875_s1), MT-ND4 (Hs02596876_g1), MT-CO2 (Hs02596865_g1), MT-CO3 (Hs02596866_g1), HPR1T (Hs99999909_m1), TBP (Hs00427620_m1), and RPL13A (Hs03043885_g1). The relative gene expression was calculated using the delta Ct method, and the target gene expression was normalized to the mean Ct of three reference genes HPRT-1, TBP, and RPL13A.

**Western blotting**
Cells were washed twice with ice-cold PBS and lysed in 1% sodium dodecyl sulfate buffer for 10 min, then passed through a QIAshredder (79654, QIAGEN) and centrifuged for 15 min at 14,000 × g. The supernatant was subsequently collected and protein concentration quantified using the BCA assays (23225, Thermo Fisher Scientific). To assess target protein expression, 10 μg lysates were loaded into 4–20% Mini-PROTEAN TGX Stain-Free Protein Gels (Bio-Rad Laboratories AB, Solna, Sweden) and separated, followed by transfer of polyvinylidene difluoride (PVDF) membranes (1704156, Bio-Rad Laboratories AB). After blocking in 5% bovine serum albumin (BSA) solution for 1 hr, the membranes were incubated with primary antibodies against MTIF3 (14219-1-AP, Proteintech), OXPHOS complex (45-8199, Thermo Fisher Scientific), FABP4, ACC, FAS (12589, Cell Signalling Technology), ATP8 (26723-1-AP, Proteintech), ND2 (19704-1-AP, Proteintech), CYTB (55090-1-AP, Proteintech), and corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-mouse IgG, Cell Signalling Technology; anti-rabbit IgG, Cell Signalling Technology). TBS with 0.1% (vol/vol) Tween-20 was used for membrane washing, and TBS with 2% BSA was used for antibody incubation. To visualize the blots, Clarity western ECL substrate was added to the membrane and a CCD camera used to acquire images and Image Lab software (Bio-Rad Laboratories AB, Solna, Sweden) were used to develop the images. ImageJ software was used to quantify the protein bands. After detection of the protein targets, the membranes were stripped using Restore Western Blot Stripping Buffer (21059, Thermo Fisher Scientific) and blotted using anti-β-Actin antibody (4967, Cell Signaling Technology) or anti-GAPDH antibody (ab37168, Abcam).

**Blue Native polyacrylamide gel electrophoresis and immunoblotting**
Differentiated scrambled control and MTIF3 knockout hWAs-iCas9 cells were adapted to 5.5 mM glucose growth medium for 3 days to mimic the physiological glucose concentration. The Blue Native
polycrylamide gel electrophoresis (BN-PAGE) was performed as described previously (Singh and Duchen, 2022). Briefly, mitochondria were isolated using Mitochondria Isolation Kit (89874, Thermo Fisher Scientific). NativePAGE Sample Prep Kit (BN2008, Invitrogen) was then used for mitochondrial protein extraction and BN-PAGE sample preparation. For native gel electrophoresis, 20 µg mitochondrial protein was loaded to precast 3–12% gradient Blue Native gels (BN1001, Invitrogen) and separated according to the manufacturer’s instructions. The proteins were then electroblotted onto PVDF membrane and probed with anti-OXPHOS antibody cocktail (45-8199, Thermo Fisher Scientific) and a corresponding secondary antibody. The blots were then imaged and analyzed as described above.

**Relative mitochondrial content measurement**

To examine the effects of MTIF3 knockout on mitochondrial biogenesis in white adipocytes, relative amount of mtDNA was quantified using a qPCR-based method described previously (Ajaz et al., 2015). Briefly, total DNA was extracted and quantified using QIAamp DNA Mini Kit (catalogue number: 56304, QIAGEN) from scrambled control and MTIF3 knockout cells. For qPCR, equal amounts of total DNA from each sample were mixed with SYBR Green master mix (catalogue number: A25742, Thermo Fisher Scientific) and with primers targeting mitochondrial and nuclear genes, then the samples were run on ViiA7 qRT-PCR system (PE Applied Biosystems, Foster City, CA, USA). The relative mtDNA content was calculated as ΔCt (Ct of nuclear target − Ct of mitochondrial target).

**Mitochondrial function in MTIF3 knockout adipocytes**

To directly assess the effects of MTIF3 on mitochondrial respiration in adipocytes we used the Seahorse XF (Seahorse Biosciences, North Billerica, MA) to measure cellular respiration OCR under different conditions. hWAs-iCas9 cells were seeded at 8000 cells/well in a Seahorse 24-well plate, then differentiated and induced for MTIF3 knockout or with scrambled control, as described above. Then, cells were adapted in 1 g/l growth medium (31885049, Thermo Fisher Scientific) for 3 days. Mitochondrial function was then assessed using the Seahorse XF-24 instrument according to a protocol optimized for the adipocyte cell line. Briefly, to measure OCR independent of oxidative phosphorylation, 2 µM oligomycin (O4876, Sigma-Aldrich) was added to the cells. Subsequently, 2 µM FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone) (C2920, Sigma-Aldrich) and 5 µM respiratory chain inhibitors: rotenone (R8875, Sigma-Aldrich) and antimycin A (A8674, Sigma-Aldrich) were added to measure maximal respiration and basal rates of non-mitochondrial respiration. Cells were then frozen at −80°C for at least 4 hr, then the plate was dried, and DNA was extracted with CyQUANT Cell Lysis Buffer (C7027, Thermo Fisher Scientific). Total DNA was then quantified by Quant-iT PicoGreen dsDNA Assay Kit (P7589, Thermo Fisher Scientific) against a lambda DNA-generated standard curve.

**Endogenous long chain fatty acid oxidation in adipocytes**

The Seahorse mitochondrial analyzer was used to test the effects of MTIF3 loss on endogenous long chain fatty acid oxidation in adipocytes. Prior to the assay, adipocytes were incubated overnight with substrate-limited medium: DMEM (A14430, Thermo Fisher Scientific); 0.5 mM glucose (103577-100, Angilent); 1.0 mM glutamine (103579-100, Angilent); 0.5 mM carnitine (C0283, Sigma-Aldrich); 1% FBS (SV30160.03, HyClone). On day of the assay, the substrate-limited medium was replaced with FAO assay medium: 1× Krebs-Henseleit Buffer (KHB) was supplemented with 2.5 mM glucose, 0.5 mM carnitine, and 5 mM N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES), and the pH was adjusted to pH 7.4 with NaOH. The cells were then treated for 15 min with either 40 µM etomoxir (E1905, Sigma-Aldrich) or only with the solvent (dimethyl sulfoxide, DMSO). Etomoxir inhibits carnitine palmitoyltransferase (CPT)-1 and diglyceride acyltransferase (DGAT) activity in mitochondria, and thus inhibits mitochondrial fatty acid oxidation (Xu et al., 2003; Griesel et al., 2010). The OCR was then measured as described above.

**Mass spectrometry-based metabolite profiling**

The mature hWAs-iCas9 adipocytes were firstly induced for MTIF3 knockout, followed by glucose restriction challenge as described above. The cells were quenched on dry ice and metabolites were extracted using a previously optimized protocol (Danielsson et al., 2010).

For analysis of low molecular weight metabolites, extracts were reconstituted in 100 µl of MeOH/water (8/2, vol/vol) and 60 µl was transferred to new Eppendorf tubes and evaporated to dryness.
using a miVac concentrator (SP Scientific, NY) for 3 hr at 30°C. Dried samples were methoximated using 20 µl of methoxyamine hydrochloride in pyridine (Thermo Scientific, MA) by shaking at 3000 rpm for 30 min at room temperature (VWR, PA). Afterward, 20 µl of N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) + 1% trimethylsilyl chloride (Thermo Scientific, MA) was added to each sample and shaken at 3000 rpm at room temperature for 1 hr. Samples were transferred to glass vials and immediately analyzed using an Agilent 6890 gas chromatograph connected to an Agilent 5975CL VL MSD mass spectrometer controlled by MassHunter Workstation software 10.0 (Agilent, Atlanta, GA). One µl sample was injected at 270°C on an HP-5MS column (30 m length, 250 µm ID, 0.25 µm phase thickness), with a helium gas flow rate of 1 ml/min and a temperature gradient starting at 70°C for 2 min, increasing 15°C/min to 320°C and held for 2 min. Data were acquired using electron ionization at 70 eV in either full scan (50–550 m/z) or single ion monitoring mode. The MS-DIAL version 4.7 was used for raw peak extraction, peak alignment, deconvolution, peak annotation, and integration of peaks.

Amino acids and free fatty acids were chemically derivatized and analyzed using a previously described method (Meng et al., 2021). Briefly, 40 µl of the samples were mixed with 20 µl of 3-nitrophenylhydrazine (3-NPH) (Sigma-Aldrich, MO), followed by addition of 20 µl of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (Thermo Scientific, MA) and shaking at 3000 rpm at room temperature for 1 hr. Samples were analyzed using an Agilent 1260 ultra-performance liquid chromatograph coupled with an Agilent 6495 tandem mass spectrometer and controlled by MassHunter version 8.0 (Agilent Technologies, CA). Three µl sample was injected on an Agilent Eclipse RRHD C18 column (2.1 × 150 mm, 1.8 µm) (Agilent Technologies, CA) with a flow rate of 0.6 ml/min and a column oven temperature of 50°C. The mobile phases A and B were 0.1% formic acid (Fisher Chemical, Prague, Czech Republic) in Milli-Q water (Merck, Millipore, MO) and acetonitrile (VWR, Paris, France), respectively. Gradient elution was performed as follows: held at 5% B from 0 to 1 min, changed linearly to 90% B in 10 min, changed from 90% B to 100% B in 13 min, held at 100% B for 2 min, returned to 5% B (initial condition) in 0.1 min, and held at 5% B for 2 min. Analyses were conducted in negative electrospray ionization mode (ESI) mode with the nebulizer gas pressure set at 20 psi, ion capillary voltage at 2500 V, gas temperature at 150°C, and sheath gas temperature at 250°C. Data were recorded in multiple reaction monitoring (MRM) mode, with two transitions for each analyte.

**Lipolysis quantification in differentiated hWAs cells**

Differentiated scrambled control or MTIF3 knockout cells were washed twice with PBS and then incubated with DMEM containing 2% free fatty acid-free BSA for 2 hr. For the insulin or isoproterenol-stimulated lipolysis, 100 nM insulin (I2643, Sigma-Aldrich) or 10 µM isoproterenol (1351005, Sigma-Aldrich) was added in the medium separately. After the incubation, the medium was collected, and the glycerol content was measured using Glycerol-Glo Assay (J3150, Promega).

**Total triglyceride measurement**

Triglyceride-Glo Assay kit (J3161, Promega) was used to quantify total triglyceride content in scrambled control or MTIF3 knockout cells cultured either in 25 mM glucose or glucose restriction medium. Briefly, cells were collected in 50 µl kit lysis buffer at room temperature for 1 hr. Then 2 µl lysate was mixed with 8 µl glycerol lysis solution with lipase, and incubated at 37°C for 30 min. Subsequently, 10 µl glycerol solution was mixed with 10 µl glycerol detection solution supplemented with reductase substrate and kinetic enhancer, and transferred into a 384-well plate. After 1-hr incubation at room temperature, the luminescence was detected using CLARIOStar plate reader (BMG Labtech, Germany), and the triglyceride concentration was calculated using a standard curve generated from glycerol standards and normalized to total protein measured using BCA assays (23227, Thermo Fisher Scientific).

**Statistics**

For each assay, the number of biological and technical replicates, standard deviation and statistical significance are reported in the figure legends. Hypothesis tests were performed using two-tailed Student’s t-test, one-way ANOVA, or paired t-test. A nominal p value of <0.05 was considered statistically significant. All analyses were undertaken using Prism GraphPad 9.0 software (La Jolla California,
USA), SIMCA 17.0 (Sartorius Stedim Data Analytics, Malmö, Sweden), R studio 1.4, and Microsoft Excel 365. For the metabolome data, ANOVA (aov) was performed in R with genotype and glucose concentration as independent variables with Tukey’s test post hoc (TukeyHSD). Significance was defined as $q < 0.05$ using multiple testing adjustment according to the false discovery rate ($p$-adjust).

Acknowledgements

We thank Jennifer Doudna (UC Berkeley) for initial support with concepts relating to using CRISPR in in vitro studies of gene–environment interactions. We also thank Yu-Hua Tseng in Joslin Diabetes Centre for providing the hWAs cells.

This work was supported by China Scholarship Council (201708420158 to Mi Huang); the European Commission (ERC-2015-CoG-681742 NASCENT to PWF), and Swedish Research Council (Distinguish Young Research Reward in Medicine) (to PWF), LUDC-IRC and The Swedish Research Council (to HM), and by The Albert Påhlsson Foundation (to SK).

Additional information

Funding

| Funder                          | Grant reference number          | Author          |
|---------------------------------|---------------------------------|-----------------|
| European Research Council       | ERC-2015-CoG-681742 NASCENT    | Paul W Franks   |
| Vetenskapsrådet                  |                                 | Hindrik Mulder  |
| LUDC-IRC                        |                                 | Hindrik Mulder  |
| China Scholarship Council       | 201708420158                    | Mi Huang        |
| Albert Påhlsson Foundation      |                                 | Sebastian Kalamajski |
| The Crafoord Foundation         | 20210571                        | Sebastian Kalamajski |

The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.

Author contributions

Mi Huang, Formal analysis, Investigation, Methodology, Writing – original draft; Daniel Coral, Formal analysis, Investigation, Writing – original draft; Hamidreza Ardalani, Investigation, Methodology, Writing – original draft; Peter Spegel, Formal analysis, Investigation; Alham Saadat, Conceptualization, Resources, Supervision; Melina Claussnitzer, Conceptualization, Resources, Funding acquisition; Hindrik Mulder, Resources, Funding acquisition; Paul W Franks, Conceptualization, Supervision, Funding acquisition, Writing – original draft, Project administration; Sebastian Kalamajski, Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration

Author ORCIDs

Mi Huang  http://orcid.org/0000-0001-6938-5322
Hindrik Mulder  http://orcid.org/0000-0002-6593-8417
Sebastian Kalamajski  http://orcid.org/0000-0002-6600-9302

Decision letter and Author response

Decision letter  https://doi.org/10.7554/eLife.84168.sa1
Author response  https://doi.org/10.7554/eLife.84168.sa2
Additional files

Supplementary files
- Supplementary file 1. Design of fine mapping luciferase reporter assays, and association of MTIF3 locus with adiposity traits in UK Biobank. (a) Thirty-one SNPs in tight linkage disequilibrium ($r^2 ≥ 0.8$) with the lead variant rs1885988 tiled down into 12 DNA segments of the MTIF3 gene for luciferase reporter assay. To fine map the transcriptional regulatory regions in the MTIF3 locus, we first identified the common genetic variants which were in tight linkage disequilibrium ($r^2 ≥ 0.8$) with the lead variant rs1885988 in HaploReg v4.1. The identified 31 SNPs were tiled down into 12 DNA segments of the MTIF3 gene depending on PCR primer design constraints. (b) SNPs in MTIF3 locus associated with body mass index (BMI), whole-body fat mass and arm fat mass (right). We checked the rapid GWAS analysis results from 337,000 samples in the UK Biobank, which were made available by Benjamin Neale's lab and visualized in Oxford BIG browser, we found SNPs in MTIF3 locus showed nominal associations with body weight-related traits including BMI, whole-body fat mass and arm fat mass (right).

- MDAR checklist

Data availability
All data generated or analyzed in this study are included in the figures and the source data files. Source data files are provided for Figures 3 and 4, and for Figure 3—figure supplement 1.

References
Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. 2006. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. The New England Journal of Medicine 355:763–778. DOI: https://doi.org/10.1056/NEJMoa055643, PMID: 16926275
Ajaz S, Czajka A, Malik A. 2015. Accurate measurement of circulating mitochondrial DNA content from human blood samples using real-time quantitative PCR. Methods in Molecular Biology 1264:117–131. DOI: https://doi.org/10.1007/978-1-4939-2257-4_12, PMID: 25789388
Appleton SL, Seaborn CJ, Visvanathan R, Hill CL, Gill TK, Taylor AW, Adams RJ, North West Adelaide Health Study T. 2013. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 36:2388–2394. DOI: https://doi.org/10.2337/dc12-1971, PMID: 23491523
Aprile M, Cataldi S, Perfetto C, Ambrosio MR, Italiani P, Tatè R, Blüher M, Ciccodicola A, Costa V. 2020. In-vitro-generated hypertrophic-like adipocytes displaying PPARG isoforms unbalance recapitulate adipocyte dysfunctions in vivo. Cells 9:1284. DOI: https://doi.org/10.3390/cells9012047, PMID: 32455814
Bhargava K, Spremulli LL. 2005. Role of the N- and C-terminal extensions on the activity of mammalian mitochondrial translational initiation factor 3. Nucleic Acids Research 33:7011–7018. DOI: https://doi.org/10.1093/nar/gki1007, PMID: 16340009
Böhm A, Keuper M, Meile T, Zdichavsky M, Fritsche A, Häring HU, de Angelis MH, Staiger H, Franko A. 2020. Increased mitochondrial respiration of adipocytes from metabolically unhealthy obese compared to healthy obese individuals. Scientific Reports 10:12407. DOI: https://doi.org/10.1038/s41598-020-69016-9, PMID: 32709986
Boudina S, Graham TE. 2014. Mitochondrial function/dysfunction in white adipose tissue. Experimental Physiology 99:1168–1178. DOI: https://doi.org/10.1113/exphys2014.081414, PMID: 25128326
Chicherin IV, Paleva MV, Levittski SA, Dashinimaev EB, Krasheninnikov IA, Kamenski P. 2020. Initiation factor 3 is dispensable for mitochondrial translation in cultured human cells. Scientific Reports 10:7110. DOI: https://doi.org/10.1038/s41598-020-64139-5, PMID: 32346061
Chu AY, Deng X, Fisher VA, Drong A, Zhang Y, Feitosa MF, Liu C-T, Weeks O, Choh AC, Duan Q, Dyer TD, Eicher JD, Guo X, Heard-Costa NL, Kacprowski T, Kent JW Jr, Lange LA, Liu X, Lohman K, Lu L, et al. 2017. Multiethnic genome-wide meta-analysis of ectopic fat depots identifies loci associated with adipocyte development and differentiation. Nature Genetics 49:125–130. DOI: https://doi.org/10.1038/ng.3738, PMID: 27918534
Civitarese AE, Carling S, Heilbronn LK, Bulmer MH, Ukoopova B, Deutsch WA, Smith SR, Ravussin E, CALERIE Pennington Team. 2007. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLOS Medicine 4:e76. DOI: https://doi.org/10.1371/journal.pmed.0040076, PMID: 17341128
Danielsson APH, Moritz T, Mulder H, Spégl P. 2010. Development and optimization of a metabolomic method for analysis of adherent cell cultures. Analytical Biochemistry 404:30–39. DOI: https://doi.org/10.1016/j.ab.2010.04.013, PMID: 20417172
Denis GV, Obin MS. 2013. "metabolically healthy obesity": origins and implications. Molecular Aspects of Medicine 34:59–70. DOI: https://doi.org/10.1016/j.mam.2012.10.004, PMID: 23068072
Gregoire FM, Smas CM, Sul HS. 1998. Understanding adipocyte differentiation. Physiological Reviews 78:783–809. DOI: https://doi.org/10.1152/physrev.1998.78.3.783, PMID: 9674695
Griesel BA, Weems J, Russell RA, Abel ED, Humphries K, Olson AL. 2010. Acute inhibition of fatty acid import inhibits GLUT4 transcription in adipose tissue, but not skeletal or cardiac muscle tissue, partly through liver X receptor (LXR) signaling. *Diabetes* **59:**800–807. DOI: https://doi.org/10.2373/diab.09-1542, PMID: 20103707

Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA, Wilborn R, Larsson NG. 2004. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. *PNAS* **101:**3136–3141. DOI: https://doi.org/10.1073/pnas.0308710100, PMID: 14978272

Heinonen S, Buzkova J, Muniandy M, Rakskon M, Ollikainen M, Ismail K, Hakkarainen A, Lundbom J, Lundbom N, Voutteenahko H, Mollanen E, Kaprio J, Rissanen A, Suomalainen A, Pietiläinen KH. 2015. Impaired mitochondrial biogenesis in adipose tissue in acquired obesity. *Diabetes* **64:**3135–3145. DOI: https://doi.org/10.2337/db14-1937, PMID: 25927572

Heinonen S, Jokinen R, Rissanen A, Pietiläinen KH. 2020. White adipose tissue mitochondrial metabolism in health and in obesity. *Obesity Reviews* **21:**e12958. DOI: https://doi.org/10.1111/obr.12958, PMID: 31777187

Jokinen R, Rinnankoski-Tuikka R, Kaye S, Saarinen L, Heinonen S, Myöhänen M, Rappou E, Jukarainen S, Jokinen R, Rissanen A, Pessa A, Velagapudi V, Virtanen KA, Piirinen E, Pietiläinen KH. 2018. Adipose tissue mitochondrial capacity associates with long-term weight loss success. *International Journal of Obesity* **42:**817–825. DOI: https://doi.org/10.1038/s41366-017-0299, PMID: 29203860

Kaaman M, Sparks LM, van Harmelen V, Smith SR, Sjolín E, Dahlman I, Arner P. 2007. Strong association between mitochondrial DNA copy number and lipogenesis in human white adipose tissue. *Diabetologia* **50:**2526–2533. DOI: https://doi.org/10.1007/s00125-007-0818-6, PMID: 17879081

Kamble PG, Hetty S, Vranic M, Almby K, Castillejo-López C, Abalo XM, Pereira MJ, Eriksson JW. 2020. Proof-of-concept for CRISPR/cas9 gene editing in human preadipocytes: deletion of FKBP5 and PPARG and effects on adipocyte differentiation and metabolism. *Scientific Reports* **10:**10565. DOI: https://doi.org/10.1038/s41598-020-67293-y, PMID: 32601291

Kuzmenko A, Atkinson GC, Levitskii S, Zenkin N, Tenson T, Hauryliuk V, Kamenski P. 2014. Mitochondrial translation initiation machinery: conservation and diversification. *Biochimie* **100:**132–140. DOI: https://doi.org/10.1016/j.biochi.2013.07.024, PMID: 23954798

Larson-Meyer DE, Heilbronn LC, Redman LM, Newcomer BR, Frisard MI, Anton S, Smith SR, Alfonso A, Ravussin E. 2006. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. *Diabetes Care* **29:**1337–1344. DOI: https://doi.org/10.2337/dc05-2565, PMID: 16732018

Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Mägi R, Randall JC, Winkler TW, et al. 2015. Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518:**197–206. DOI: https://doi.org/10.1038/nature14177, PMID: 25673413

Lotta LA, Wittemans LBL, Zuber V, Stewart ID, Sharp SJ, Luan J, Day FR, Li C, Bowker N, Cai L, De Lucia Rolfe E, Khaw K-T, Perry JRB, O’Rahilly S, Scott RA, Savage DB, Burgess S, Wareham NJ, Langenberg C. 2018. Association of genetic variants related to glucose/insulin vs abdominal fat distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors. *JAMA* **320:**2553–2563. DOI: https://doi.org/10.1001/jama.2018.19329, PMID: 30575882

Maechler P, Wollheim CB. 2001. Mitochondrial function in normal and diabetic beta-cells. *Nature* **414:**807–812. DOI: https://doi.org/10.1038/3414807a, PMID: 11742413

May CE, Rosander J, Gottfried J, Dennis E, Dus M. 2020. Dietary sugar inhibits satiation by decreasing the central processing of sweet taste. *elife* **9:**e54530. DOI: https://doi.org/10.7554/elife.54530, PMID: 32539934

Meng X, Pang H, Sun F, Jin X, Wang B, Yao K, Yao L, Wang L, Hu Z. 2021. Simultaneous 3-nitrophenylhydrizin derivatization strategy of carboxyl, carbonyl and phospholipid submetabolome for LC-MS/MS-based targeted metabolomics with improved sensitivity and coverage. *Analytical Chemistry* **93:**10075–10083. DOI: https://doi.org/10.1021/acs.analchem.1c00767, PMID: 34270209

Nettleton JA, Folli JL, Ngwa JS, Smith CE, Ahmad S, Tanaka T, Wojczynsky MK, Voortman T, Lemaître RN, Kristiansson K, Nuotio M-L, Houston DK, Peräilä M-M, Qi Q, Sonestedt E, Manichaikul A, Kanoni S, Ganna A, Mikkilä V, North KE, et al. 2015. Gene × dietary pattern interactions in obesity: analysis of up to 68 317 adults of European ancestry. *Human Molecular Genetics* **24:**4728–4738. DOI: https://doi.org/10.1093/hmg/ddv186, PMID: 25994509

Papandonatos GD, Pan Q, Paweski NM, Delahanty LM, Peter I, Erra B, Ahmad S, Harden M, Chen L, Fontanillas P, GIANT Consortium, Wagenknecht LE, Kahn SE, Wing RR, Jablonski KA, Huggins GS, Knowler WC, Flores JC, McCaffery JM, Franks PW, et al. 2015. Genetic predisposition to weight loss and discordant for BMI: pathways behind acquired obesity. *Diabetes* **64:**4312–4321. DOI: https://doi.org/10.2337/db15-0441, PMID: 26253612

Phielix E, Meex R, Moonen-Kornips E, Hesselink MKC, Schrauwen P. 2010. Exercise training increases mitochondrial content and ex vivo mitochondrial function similarly in patients with type 2 diabetes and in control individuals. *Diabetologia* **53:**1714–1721. DOI: https://doi.org/10.1007/s00125-010-1764-2, PMID: 20422397

Pietiläinen KH, Naukkarinen J, Rissanen A, Saharinen J, Ellonen P, Keränen H, Suomalainen A, Götz A, Suortti T, Yki-Järvinen H, Oresic M, Kaprio J, Peltonen L. 2008. Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity. *PLoS Medicine* **5:**e51. DOI: https://doi.org/10.1371/journal.pmed.0050051, PMID: 18336063
Poulos SP, Dodson MV, Hausman GJ. 2010. Cell line models for differentiation: preadipocytes and adipocytes. *Experimental Biology and Medicine* 235:1185–1193. DOI: https://doi.org/10.1258/ebm.2010.010063, PMID: 20864461

Rasmussen-Tovik LJ, Baldridge AS, Pacheco JA, Aufox SA, Kim K-YA, Silverstein JC, Denham EW, Hungness E, Smith ME, Greenland P. 2015. Rs4771122 predicts multiple measures of long-term weight loss after bariatric surgery. *Obesity Surgery* 25:2225–2229. DOI: https://doi.org/10.1007/s11695-015-1872-7, PMID: 26337695

Rudler DL, Hughes LA, Perks KL, Richman TR, Kuznetsova I, Ermer JA, Abudulai LN, Shearwood AMJ, Viola HM, Hool LC, Siria SJ, Rackham O, Filipovska A. 2019. Fidelity of translation initiation is required for coordinated respiratory complex assembly. *Science Advances* 5:eaa12118. DOI: https://doi.org/10.1126/sciadv.aay2118, PMID: 31903419

Ruiz-Ojeda FJ, Rupérez AI, Gomez-Llorente C, Gil A, Aguilera CM. 2016. Cell models and their application for studying adipogenic differentiation in relation to obesity: a review. *International Journal of Molecular Sciences* 17:1040. DOI: https://doi.org/10.3390/ijms170101040, PMID: 27376239

Sakers A, De Siqueira MK, Seale P, Villanueva CJ. 2022. Adipose-Tissue plasticity in health and disease. *Cell* 185:419–446. DOI: https://doi.org/10.1016/j.cell.2021.12.016, PMID: 35120662

Shamsi F, Tseng YH. 2017. Protocols for generation of immortalized human brown and white preadipocyte cell lines. *Methods in Molecular Biology* 1566:77–85. DOI: https://doi.org/10.1007/978-1-4939-6820-6_8, PMID: 28244042

Singh K, Duchen MR. 2022. Analysis of organization and activity of mitochondrial respiratory chain complexes in primary fibroblasts using blue native page. *Methods in Molecular Biology* 2497:339–348. DOI: https://doi.org/10.1007/978-1-0716-2309-1_25, PMID: 35771456

Thomas D. 2010. Gene -- environment- wide association studies: emerging approaches. *Nature Reviews. Genetics* 11:259–272. DOI: https://doi.org/10.1038/nrg2764, PMID: 20212493

Toledo FGS, Menshikova EV, Ritov VB, Azuma K, Radikova Z, DeLany J, Kelley DE. 2007. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. *Diabetes* 56:2142–2147. DOI: https://doi.org/10.2337/db07-0141, PMID: 17536063

Tormos KV, Anso E, Hamanaka RB, Eisenbart J, Joseph J, Kalyanaraman B, Chandel NS. 2011. Mitochondrial complex III ROS regulate adipocyte differentiation. *Cell Metabolism* 14:537–544. DOI: https://doi.org/10.1016/j.cmet.2011.08.007, PMID: 21982713

Wang G, Yang L, Grishin D, Rios X, Ye LY, Hu Y, Li K, Zhang D, Church GM, Pu WT. 2017. Efficient, footprint-free human iPSC genome editing by consolidation of cas9/CRISPR and piggyBac technologies. *Nature Protocols* 12:88–103. DOI: https://doi.org/10.1038/nprot.2016.152, PMID: 27929521

Ward LD, Kellis M. 2012. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Research* 40:D930–D934. DOI: https://doi.org/10.1093/nar/gkr917, PMID: 21982713

Xue R, Lynes MD, Dreyfuss JM, Shamsi F, Schulz TJ, Zhang H, Huang TL, Townsend KL, Li Y, Takahashi H, Weiner LS, White AP, Lynes MS, Rubin LL, Goodyear LJ, Cypess AM, Tseng Y-H. 2015. Clonal analyses and gene profiling identify genetic biomarkers of the thermogenic potential of human brown and white preadipocytes. *Nature Medicine* 21:760–768. DOI: https://doi.org/10.1038/nm.3881, PMID: 26076036

Zhu Q, An YA, Scherer PE. 2022. Mitochondrial regulation and white adipose tissue homeostasis. *Trends in Cell Biology* 32:351–364. DOI: https://doi.org/10.1016/j.tcb.2021.10.008, PMID: 34810062
## Appendix 1—key resources table

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| **Gene** (Homo sapiens)           | MTIF3       | UCSC Genome Browser | GRCh38/hg38 |                        |
| **Cell line** (Homo sapiens)      | hWAs        | Tseng laboratory at Joslin Diabetes Center | Xue et al., 2015 |                        |
| **Cell line** (Homo sapiens)      | hWAs-iCas9  | This paper          |             | Cell line maintained at Lund University Diabetes Center |
| **Antibody**                      | Anti-MTIF3 (rabbit polyclonal antibody) | Proteintech | Cat: 14219-1-AP | WB (1:2000) |
| **Antibody**                      | Anti-OXPHOS antibody cocktail (mouse polyclonal antibody) | Thermo Fisher Scientific | Cat: 45-8199 | WB (1:1000) |
| **Antibody**                      | Anti-FABP4 (rabbit polyclonal antibody) | Cell Signalling Technology | Cat: 12589 | WB (1:1000) |
| **Antibody**                      | Anti-ACC rabbit polyclonal antibody | Cell Signalling Technology | Cat: 12589 | WB (1:1000) |
| **Antibody**                      | Anti-FAS rabbit polyclonal antibody | Cell Signalling Technology | Cat: 12589 | WB (1:1000) |
| **Antibody**                      | Anti-ATP8 (rabbit polyclonal antibody) | Proteintech | Cat: 26273-1-AP | WB (1:2000) |
| **Antibody**                      | Anti-ND2 (rabbit polyclonal antibody) | Proteintech | Cat: 19704-1-AP | WB (1:2000) |
| **Antibody**                      | Anti-CYTB (rabbit polyclonal antibody) | Proteintech | Cat: 55090-1-AP | WB (1:2000) |
| **Antibody**                      | Anti-β-Actin (rabbit polyclonal antibody) | Cell Signalling Technology | Cat: #4967 | WB (1:10,000) |
| **Antibody**                      | Anti-GAPDH (rabbit polyclonal antibody) | Abcam | Cat: ab37168 | WB (1:10,000) |
| **Antibody**                      | Anti-rabbit IgG, HRP-linked Antibody (goat polyclonal antibody) | Cell Signalling Technology | Cat: #7074 | WB (1:10,000) |
| **Antibody**                      | Anti-mouse IgG, HRP-linked Antibody (horse polyclonal antibody) | Cell Signalling Technology | Cat: #7076 | WB (1:10,000) |
| **Recombinant DNA reagent**       | Super PiggyBac transposase (plasmid) | System Biosciences | PB210PA-1 |                        |
| **Recombinant DNA reagent**       | pGL4.23 vectors | Promega | E8411 |                        |
| **Recombinant DNA reagent**       | pGL4.75 CMV-Renilla reporter vectors | Promega | E6931 |                        |
| **Recombinant DNA reagent**       | pPB-rtTA-hCas9-puro-PB plasmid | doi:10.1038/nprot.2016.152 |                        |                        |
| **Sequence-based reagent**        | PCR primer (Forward) for rs67785913 genotyping | IDT | 5’-3’: GATTGGCAGTTGAGCAAGACA |                        |
| **Sequence-based reagent**        | PCR primer (Reverse) for rs67785913 genotyping | IDT | 5’-3’: ACTTGAAAATGGCCAAAGATG |                        |
| **Sequence-based reagent**        | sgRNA for rs67785913 editing | IDT | Spacer sequence: 5’TTTCAATAGAATATCCTCA-3’ |                        |
| **Sequence-based reagent**        | sgRNA for rs67785913 editing | IDT | Spacer sequence: 5’GAAGAAAAAGGGGGGACAG-3’ |                        |
| **Sequence-based reagent**        | Donor template for rs67785913 editing | IDT | ssDNA sequence: 5’TGTGGAACCTCGCAAGTCTGCCCCTTGAGGAATTTTCCTATGGAAGAAAAAAGAGGGGAGCGCAGCCGAGACCCGGGACGCCGGCTTCGAGCAGGGCCTC-3’ |                        |
| **Sequence-based reagent**        | sgRNA against MTIF3 | IDT | Design ID: Hs_Cas9 MTIF3.1 AB | Spacer sequence: 5’GCAATTTGGGGACAACTGTG-3’ |                        |
| **Sequence-based reagent**        | Taqman assay for MTIF3 | Thermo Fisher Scientific | Hs0074538_m1 |                  |

*Appendix 1 Continued on next page*
### Appendix 1 Continued

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Sequence-based reagent            | Taqman assay for GTF3A | Thermo Fisher Scientific | Hs00157851_m1 |                        |
| Sequence-based reagent            | Taqman assay for ADIPOQ | Thermo Fisher Scientific | Hs00977214_m1 |                        |
| Sequence-based reagent            | Taqman assay for PPARG | Thermo Fisher Scientific | Hs01115513_m1 |                        |
| Sequence-based reagent            | Taqman assay for CEBPA | Thermo Fisher Scientific | Hs00269972_s1 |                        |
| Sequence-based reagent            | Taqman assay for SREBF1 | Thermo Fisher Scientific | Hs02561944_s1 |                        |
| Sequence-based reagent            | Taqman assay for FASN | Thermo Fisher Scientific | Hs0106522_m1 |                        |
| Sequence-based reagent            | Taqman assay for TFAM | Thermo Fisher Scientific | Hs01073348_g1 |                        |
| Sequence-based reagent            | Taqman assay for MT-CO1 | Thermo Fisher Scientific | Hs02596864_g1 |                        |
| Sequence-based reagent            | Taqman assay for PRDM16 | Thermo Fisher Scientific | Hs0023161_m1 |                        |
| Sequence-based reagent            | Taqman assay for TOMM20 | Thermo Fisher Scientific | Hs03276810_g1 |                        |
| Sequence-based reagent            | Taqman assay for CPT1B | Thermo Fisher Scientific | Hs00189258_m1 |                        |
| Sequence-based reagent            | Taqman assay for ACADM | Thermo Fisher Scientific | Hs00936584_m1 |                        |
| Sequence-based reagent            | Taqman assay for ACAT1 | Thermo Fisher Scientific | Hs00608002_m1 |                        |
| Sequence-based reagent            | Taqman assay for ABHD5 | Thermo Fisher Scientific | Hs01104373_m1 |                        |
| Sequence-based reagent            | Taqman assay for PNPTA2 | Thermo Fisher Scientific | Hs00386101_m1 |                        |
| Sequence-based reagent            | Taqman assay for ACACB | Thermo Fisher Scientific | Hs01565914_m1 |                        |
| Sequence-based reagent            | Taqman assay for MT-ND1 | Thermo Fisher Scientific | Hs02596873_s1 |                        |
| Sequence-based reagent            | Taqman assay for MT-ND2 | Thermo Fisher Scientific | Hs02596874_g1 |                        |
| Sequence-based reagent            | Taqman assay for MT-ND3 | Thermo Fisher Scientific | Hs02596875_s1 |                        |
| Sequence-based reagent            | Taqman assay for MT-ND4 | Thermo Fisher Scientific | Hs02596876_g1 |                        |
| Sequence-based reagent            | Taqman assay for MT-CO2 | Thermo Fisher Scientific | Hs02596865_g1 |                        |
| Sequence-based reagent            | Taqman assay for MT-CO3 | Thermo Fisher Scientific | Hs02596866_g1 |                        |
| Sequence-based reagent            | Taqman assay for HPRT-1 | Thermo Fisher Scientific | Hs99999909_m1 |                        |
| Sequence-based reagent            | Taqman assay for TBP | Thermo Fisher Scientific | Hs00427620_m1 |                        |
| Sequence-based reagent            | Taqman assay for RPL13A | Thermo Fisher Scientific | Hs03043885_g1 |                        |
| Commercial assay or kit           | DNeasy Blood and Tissue kit | QIAGEN | 69506 |                        |
| Commercial assay or kit           | Dual-Glo Stop&Glo reagents | Promega | E2920 |                        |

Appendix 1 Continued on next page
| Reagent type or resource | Designation | Source or reference | Identifiers | Additional information |
|--------------------------|-------------|---------------------|-------------|------------------------|
| Commercial assay or kit  | Alt-R S.p. Cas9 D10A Nickase V3 | IDT | 1081058 |                        |
| Commercial assay or kit  | Nuclease reagent L | Lonza | VCA-1005 |                        |
| Commercial assay or kit  | Alt-R HDR Enhancer V2 | IDT | 10007921 |                        |
| Commercial assay or kit  | QuickExtract DNA Extraction Solution | Lucigen | QI09050 |                        |
| Commercial assay or kit  | Alt-R Genome Editing Detection Kit | IDT | 1075932 |                        |
| Commercial assay or kit  | Mitochondrial isolation kit | Thermo Fisher Scientific | B9674 |                        |
| Commercial assay or kit  | NativePAGE Sample Prep Kit | Invitrogen | BN2008 |                        |
| Commercial assay or kit  | Quant-IT PicoGreen dsDNA Assay Kit | Thermo Fisher Scientific | P7589 |                        |
| Commercial assay or kit  | Triglyceride-Glo Assay kit | Promega | J3161 |                        |
| Commercial assay or kit  | Glycerol-Glo Assay | Promega | J3150 |                        |
| Chemical compound, drug  | Insulin | Sigma-Aldrich | I2643 |                        |
| Chemical compound, drug  | Isoproterenol | Sigma-Aldrich | 1351005 |                        |
| Chemical compound, drug  | Glucose | Angilent | 103577-100 |                        |
| Chemical compound, drug  | Glutamine | Angilent | 103579-100 |                        |
| Chemical compound, drug  | Carnitine | Sigma-Aldrich | C0283 |                        |
| Chemical compound, drug  | Pyridine | Sigma-Aldrich | A13141.22 |                        |
| Chemical compound, drug  | N-Methyl-N-(trimethylsilyl) trifluoroacetamide | Thermo Scientific | 019378.K2 |                        |
| Chemical compound, drug  | Trimethylsilyl chloride | Thermo Scientific | A12535.30 |                        |
| Chemical compound, drug  | 3-Nitrophenyldihydrazine | Sigma-Aldrich | N21804 |                        |
| Chemical compound, drug  | 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride | Sigma-Aldrich | 22980 |                        |
| Chemical compound, drug  | Formic acid | Sigma-Aldrich | E1905 |                        |
| Chemical compound, drug  | Etomoxir | Sigma-Aldrich | O4876 |                        |
| Chemical compound, drug  | FCCP | Sigma-Aldrich | C2920 |                        |
| Chemical compound, drug  | Rotenone | Sigma-Aldrich | R8875 |                        |
| Chemical compound, drug  | Antimycin A | Sigma-Aldrich | A8674 |                        |